RU2504550C2 - Длительно действующие агонисты рецепторов y2 и(или) y4 - Google Patents
Длительно действующие агонисты рецепторов y2 и(или) y4 Download PDFInfo
- Publication number
- RU2504550C2 RU2504550C2 RU2010149474/04A RU2010149474A RU2504550C2 RU 2504550 C2 RU2504550 C2 RU 2504550C2 RU 2010149474/04 A RU2010149474/04 A RU 2010149474/04A RU 2010149474 A RU2010149474 A RU 2010149474A RU 2504550 C2 RU2504550 C2 RU 2504550C2
- Authority
- RU
- Russia
- Prior art keywords
- ethoxy
- acetylamino
- acetyl
- seq
- butyrylamino
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 4
- 102000007562 Serum Albumin Human genes 0.000 claims abstract 3
- 108010071390 Serum Albumin Proteins 0.000 claims abstract 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 94
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 72
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 58
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 47
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 47
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 43
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 40
- 108010088847 Peptide YY Proteins 0.000 claims 31
- -1 Val Chemical compound 0.000 claims 31
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 29
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 29
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 29
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 29
- 229960003104 ornithine Drugs 0.000 claims 29
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 11
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims 11
- 229940124277 aminobutyric acid Drugs 0.000 claims 11
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims 10
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 10
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 101000585528 Homo sapiens Peptide YY Proteins 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 claims 2
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 claims 2
- 102000028435 Neuropeptide Y4 receptor Human genes 0.000 claims 2
- 108010002245 Neuropeptide Y4 receptor Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 229960002591 hydroxyproline Drugs 0.000 claims 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 claims 1
- 101150118523 LYS4 gene Proteins 0.000 claims 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 claims 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical group C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 108010020532 tyrosyl-proline Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 0 CC(CCCCCCCCCCCCCCCCC(NC(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(P)=O)N*)=O)=O)=O)C(O)=O)=O)=C Chemical compound CC(CCCCCCCCCCCCCCCCC(NC(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(P)=O)N*)=O)=O)=O)C(O)=O)=O)=C 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N CCc(cc1)ccc1O Chemical compound CCc(cc1)ccc1O HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N Cc(cc1)ccc1O Chemical compound Cc(cc1)ccc1O IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156360 | 2008-05-16 | ||
| EP08156360.3 | 2008-05-16 | ||
| EP09154461 | 2009-03-05 | ||
| EP09154461.9 | 2009-03-05 | ||
| PCT/EP2009/055989 WO2009138511A1 (en) | 2008-05-16 | 2009-05-18 | Long-acting y2 and/or y4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010149474A RU2010149474A (ru) | 2012-06-27 |
| RU2504550C2 true RU2504550C2 (ru) | 2014-01-20 |
Family
ID=40934036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010149474/04A RU2504550C2 (ru) | 2008-05-16 | 2009-05-18 | Длительно действующие агонисты рецепторов y2 и(или) y4 |
Country Status (12)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678312C1 (ru) * | 2013-11-15 | 2019-01-25 | Ново Нордиск А/С | Селективные соединения пептида yy и их применения |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2450374B9 (en) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| CN102573888A (zh) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | 长效y2 受体激动剂 |
| EP2498800A1 (en) * | 2009-11-13 | 2012-09-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2012006566A2 (en) | 2010-07-09 | 2012-01-12 | Amylin Pharmaceuticals, Inc. | Microcrystalline y receptor agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| EP2842965A1 (en) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin U analogs comprising serum albumin binding amino acid residue |
| WO2015071355A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| WO2015073878A1 (en) * | 2013-11-15 | 2015-05-21 | Ur Diet, Llc | Real-time satiety biofeedback |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| US20240100450A9 (en) * | 2014-01-17 | 2024-03-28 | Repligen Corporation | Sterilizing chromatography columns |
| EP3094391B1 (en) | 2014-01-17 | 2024-11-20 | Repligen Corporation | Sterilizing chromatography columns |
| CN114805527A (zh) * | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| CA3175725A1 (en) * | 2020-04-17 | 2021-10-21 | William Blackwell | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
| JP2024516395A (ja) | 2021-04-27 | 2024-04-15 | アードバーク・セラピューティクス・インコーポレイテッド | 苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005077094A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| WO2005089786A2 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| WO2006005667A2 (en) * | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| RU2275207C2 (ru) * | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| WO2007009894A2 (en) * | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
-
2009
- 2009-05-18 RU RU2010149474/04A patent/RU2504550C2/ru not_active IP Right Cessation
- 2009-05-18 JP JP2011508945A patent/JP2011520847A/ja not_active Withdrawn
- 2009-05-18 KR KR1020107027495A patent/KR20110017874A/ko not_active Withdrawn
- 2009-05-18 CN CN2009801173043A patent/CN102027007A/zh not_active Withdrawn
- 2009-05-18 AU AU2009248041A patent/AU2009248041B2/en not_active Ceased
- 2009-05-18 US US12/993,015 patent/US20110275559A1/en not_active Abandoned
- 2009-05-18 WO PCT/EP2009/055989 patent/WO2009138511A1/en not_active Ceased
- 2009-05-18 BR BRPI0912615A patent/BRPI0912615A2/pt not_active Application Discontinuation
- 2009-05-18 MX MX2010011845A patent/MX2010011845A/es not_active Application Discontinuation
- 2009-05-18 CA CA2723855A patent/CA2723855A1/en not_active Withdrawn
- 2009-05-18 EP EP09745843A patent/EP2279204A1/en not_active Withdrawn
-
2010
- 2010-10-20 IL IL208836A patent/IL208836A0/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2275207C2 (ru) * | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005077094A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| WO2005089786A2 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| WO2006005667A2 (en) * | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| WO2007009894A2 (en) * | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678312C1 (ru) * | 2013-11-15 | 2019-01-25 | Ново Нордиск А/С | Селективные соединения пептида yy и их применения |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2279204A1 (en) | 2011-02-02 |
| BRPI0912615A2 (pt) | 2016-01-26 |
| MX2010011845A (es) | 2010-11-22 |
| AU2009248041A1 (en) | 2009-11-19 |
| CA2723855A1 (en) | 2009-11-19 |
| KR20110017874A (ko) | 2011-02-22 |
| IL208836A0 (en) | 2011-01-31 |
| WO2009138511A1 (en) | 2009-11-19 |
| US20110275559A1 (en) | 2011-11-10 |
| AU2009248041B2 (en) | 2013-10-03 |
| CN102027007A (zh) | 2011-04-20 |
| RU2010149474A (ru) | 2012-06-27 |
| JP2011520847A (ja) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010149474A (ru) | Длительно действующие агонисты рецепторов y2 и(или) y4 | |
| JP2011520847A5 (cg-RX-API-DMAC10.html) | ||
| JP2011524420A5 (cg-RX-API-DMAC10.html) | ||
| JP2013543497A5 (cg-RX-API-DMAC10.html) | ||
| FI120586B (fi) | Menetelmä PTH:n ja PTHRP:n analogien valmistamiseksi, ja niiden käyttö osteoporoosin hoitoon | |
| JP2016512213A5 (cg-RX-API-DMAC10.html) | ||
| JP2010538049A5 (cg-RX-API-DMAC10.html) | ||
| JP2013518115A5 (cg-RX-API-DMAC10.html) | ||
| JP2014502252A5 (cg-RX-API-DMAC10.html) | ||
| JP2011502155A5 (cg-RX-API-DMAC10.html) | ||
| CA2752608A1 (en) | Cytotoxic conjugates having neuropeptide y receptor binding compound | |
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2013518115A (ja) | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物 | |
| JP2010515686A5 (cg-RX-API-DMAC10.html) | ||
| US20120121591A1 (en) | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 | |
| AU2014241743A1 (en) | Insulin-incretin conjugates | |
| PE20140159A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| US20180265560A1 (en) | Biphasic single-chain insulin analogues | |
| JP2012529463A5 (cg-RX-API-DMAC10.html) | ||
| JP2010538042A (ja) | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 | |
| AR071990A1 (es) | Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto | |
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| JP2012518035A5 (cg-RX-API-DMAC10.html) | ||
| US20220002373A1 (en) | Single-chain insulin analogues with poly-alanine c-domain sub-segments | |
| US20140296131A1 (en) | Truncated GLP-1 Derivatives and Their Therapeutical Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150519 |